GlassScriptPhysician profile
John Paul Sersanti
NPI 1003882697
$3,816.58
in general payments reported to CMS, 2019-2025
26 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $131 · 2021: $524 · 2022: $328 · 2023: $368 · 2024: $506 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,449.25 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Novo Nordisk INC | $554.20 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $342.19 | 2019-2024 | Trelegy Ellipta |
| Corcept Therapeutics | $310.71 | 2025 | Korlym |
| Lilly USA, LLC | $215.90 | 2019-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $149.93 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $141.79 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $114.74 | 2022 | |
| Globus Medical, INC. | $99.14 | 2025 | Senza |
| Vertiflex, INC. | $98.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.27 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.28 | 2019-2024 | Jardiance |
| Abbvie INC. | $41.48 | 2021-2022 | |
| Daiichi Sankyo INC. | $24.29 | 2021 | |
| Merck Sharp & Dohme LLC | $23.92 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.83 | 2022 | |
| Amarin Pharma, INC. | $22.37 | 2019-2020 | |
| Abbott Laboratories | $15.55 | 2025 | Aveir |
| Xeris Pharmaceuticals, INC. | $15.00 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $14.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2022 | |
| Esperion Therapeutics, INC. | $11.76 | 2021 | |
| Allergan, INC. | $11.55 | 2019 | |
| Pfizer INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sersanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.